Key points are not available for this paper at this time.
The incidence of PD-1 inhibitor-related pneumonitis was higher in NSCLC and RCC and during combination therapy. These findings contribute to enhance awareness among clinicians and support further investigations to meet the clinical needs.
Nishino et al. (Fri,) studied this question.